Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC

Pazopanib is a potent multi-targeted kinase inhibitor approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The pharmacokinetics of pazopanib is characterized by a significant inter- and intra-patient variability and a target through plasma concentration of 20.5 mg·L(−...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozbey, Agustos Cetin, Combarel, David, Poinsignon, Vianney, Lovera, Christine, Saada, Esma, Mir, Olivier, Paci, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469080/
https://www.ncbi.nlm.nih.gov/pubmed/34577627
http://dx.doi.org/10.3390/ph14090927

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469080/
https://www.ncbi.nlm.nih.gov/pubmed/34577627
http://dx.doi.org/10.3390/ph14090927

Ejemplares similares